Search Results

leading cause by 2030. 2 PDAC is biologically aggressive and often presents at a later stage, with up to 80% of patients found to have locally advanced cancer or distant metastases at the time of initial evaluation. 3 In 2011 and 2013, the treatment

W hen considering the role of radiation therapy in operable and locally advanced pancreatic cancer, it becomes necessary to examine the patterns of locoregional versus systemic failure in these disease settings. For example, data from single

treatment options for patients with locally advanced unresectable PDAC Explain the roles of systemic therapy and chemoradiation for locally advanced PDAC including optimal sequencing, recent improvements in chemotherapy, and whether radiotherapy improves

cancer is comparable to that of similarly staged colon and sigmoid cancers, 2 patients with locally advanced rectal cancer (LARC; T3-4 or node-positive LARC) experience a significantly higher local recurrence risk than their counterparts with colon

Osti MF Costa AM Bianciardi F . Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study . Tumori 2001 ; 87 : 398 – 401 . 21 Boz G De Paoli A Innocente R

Background Colon cancer is highly prevalent worldwide 1 and a major public health problem. A substantial group of patients (10%–15%) presents with locally advanced colon cancer (LACC), which has an important impact on disease management and

of immunotherapies and to harness artificial intelligence to better understand the disease. Turning to the treatment of locally advanced rectal cancer, Christopher G. Willett, MD, Professor, and Chairman, Department of Radiation Oncology, Duke

of patients continued to present with locally advanced breast cancer at City of Hope National Medical Center, an NCI-designated Comprehensive Cancer Center (COHCC) located in Southern California, where access to health care resources is readily

associated with improved oncologic outcomes, and further study may show that they improve the therapeutic outcomes for patients with locally advanced disease when given in the adjuvant setting. Multimodal treatment, incorporating both local and systemic

, 9 Metastatic and recurrent CC has a median survival of 17 months with standard-of-care frontline platinum/taxane-based chemotherapy and bevacizumab. 10 Therefore, for most node-positive locally advanced and metastatic CC, an unmet therapeutic need